Effects of MDR reversing agent combinations on the 3H-Daunomycin accumulation in drug-sensitive and drug-resistant human cancer cells

Anticancer Research

Volumn 20, Issue 4, 2000, Pages 2617-2623

  Moins, Nicole ^a   Cayre, Anne ^b   Chevillard, Sylvie ^c   Maublant, Jean ^a,b   Verrelle, Pierre ^b   Finat Duclos, Françoise ^b  

^a INSERM   (France)

^b CENTRE JEAN PERRIN   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

3H daunomycin; MDR modulation; MDR related genes; Multidrug resistance; Tumour cells

Indexed keywords

DAUNORUBICIN; S9788; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL;

ARTICLE; CANCER CELL; CELL LEVEL; CONTROLLED STUDY; DRUG ACCUMULATION; HUMAN; HUMAN CELL; ISOTOPE LABELING; MULTIDRUG RESISTANCE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIBIOTICS, ANTINEOPLASTIC; CYCLOSPORINS; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; KB CELLS; P-GLYCOPROTEIN; PIPERIDINES; TRIAZINES; VERAPAMIL;

EID: 0033853785     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Endicott JA and Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989.
2. Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
3. Lautier D, Canitrot Y, Deeley RG and Cole SP: Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52: 967-977, 1996.
4. Baggetto L: Non P-glycoprotein novel proteins involved in human cancer multidrug resistance. Bull Cancer 84: 385-390, 1997.
5. Lehnert M: Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 32A: 912-920, 1996.
6. Muller C, Bailly JD, Jaffrezou JP, Goubin F and Laurent G: Modulation pharmacologique de l'expression de la P-glycoprotéine. Bull Cancer 81: 386-391, 1994.
7. Tsuruo T, Iida H, Nojiri M, Tsukagoshi S and Sakurai Y: Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 43: 2905-2910, 1983.
8. Boesch D, Muller K, Pourtier-Manzadeno A and Loor F: Restoration of daunomycin retention in multidrug resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporine derivative. Exp Cell Res 196: 26-32, 1991.
9. Merlin JL, Guerci AP, Marchal S, Bour C, Colosetti P, Kataki A and Guerci O: Influence of SDZ-PSC 833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukemia. Br J Haematol 103: 480-487, 1998.
10. Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI and Greenberg PL: Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (valspodar). Blood 93: 787-795, 1999.
11. Soudon J, Berlion M, Lucas C, Haddad P, Bizzari JP and Calvo F: In vitro activity of S9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients. Cancer Chemother Pharmacol 36: 195-203, 1995.
12. Akiyama S, Fojo A, Hanover J.A, Pastan I and Gottesman NM: Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Genet 11: 117-126, 1985.
13. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzedoc P, Magdelenat H and Vielh P: Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77: 292-300, 1996.
14. Chevillard S, Vielh PH, Validire P, Marie JP, Faussat AM, Barbu V, Bayle C, Benard J, Bonnal C, Boutonnat J, Calvo F, Charrier J, Clary A, Colosetti P, Danel-Moore L, Decremoux P, Delvincourt C, Finat-Duclos F, Genne PH, Kataki A, Kouyoumdjian JC, Lacave R, Maugard C, Merlin JL, Mousseau M, Pinguet F, Quillien V, Raphael M, Richard B, Verrelle P and Robert J: French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris. Leukemia 11: 1095-1096, 1997.
15. 3H-daunomycin uptake in human carcinoma cells: relation to the MDR phenotype and effects of reversing agents. J Nucl Med 40: 672-676, 1999.
16. Dano K: Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim. Biophys. Acta 323: 466-483, 1973.
17. Ford JM and Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199, 1990.
18. Cros S, Guilbaud N, Berlion M, Dunn TA, Regnier G, Dhainaut A, Atassi G and Bizzari JP: In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S9788 in P388/VCR leukemia model. Cancer Chemother Pharmacol 30: 491-494, 1992.